AU2003290805A1 - Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy - Google Patents

Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy Download PDF

Info

Publication number
AU2003290805A1
AU2003290805A1 AU2003290805A AU2003290805A AU2003290805A1 AU 2003290805 A1 AU2003290805 A1 AU 2003290805A1 AU 2003290805 A AU2003290805 A AU 2003290805A AU 2003290805 A AU2003290805 A AU 2003290805A AU 2003290805 A1 AU2003290805 A1 AU 2003290805A1
Authority
AU
Australia
Prior art keywords
therapy
anticancer
gst
agent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003290805A
Other languages
English (en)
Inventor
Gail L. Brown
James G. Keck
Steven R. Schow
Hua Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telik Inc
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of AU2003290805A1 publication Critical patent/AU2003290805A1/en
Priority to AU2010200483A priority Critical patent/AU2010200483A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003290805A 2002-11-15 2003-11-14 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy Abandoned AU2003290805A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010200483A AU2010200483A1 (en) 2002-11-15 2010-02-10 Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42698302P 2002-11-15 2002-11-15
US60/426,983 2002-11-15
PCT/US2003/036209 WO2004045593A2 (en) 2002-11-15 2003-11-14 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010200483A Division AU2010200483A1 (en) 2002-11-15 2010-02-10 Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy

Publications (1)

Publication Number Publication Date
AU2003290805A1 true AU2003290805A1 (en) 2004-06-15

Family

ID=32326463

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003290805A Abandoned AU2003290805A1 (en) 2002-11-15 2003-11-14 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
AU2010200483A Abandoned AU2010200483A1 (en) 2002-11-15 2010-02-10 Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010200483A Abandoned AU2010200483A1 (en) 2002-11-15 2010-02-10 Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy

Country Status (12)

Country Link
US (2) US20040138140A1 (https=)
EP (1) EP1562564A2 (https=)
JP (2) JP2006508980A (https=)
KR (1) KR20050075018A (https=)
CN (2) CN101590229B (https=)
AR (1) AR042051A1 (https=)
AU (2) AU2003290805A1 (https=)
BR (1) BR0316364A (https=)
CA (1) CA2505377A1 (https=)
MX (1) MXPA05005200A (https=)
TW (1) TWI323662B (https=)
WO (1) WO2004045593A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
JP5371426B2 (ja) * 2004-07-09 2013-12-18 プロルックス ファーマシューティカルズ コープ． ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法
EP1833978B1 (en) * 2005-01-06 2008-10-08 Telik, Inc. Tripeptide and tetrapeptide thioethers
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
CA2715348A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
US20110021618A1 (en) * 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
WO2010086964A1 (ja) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 がん治療のための併用療法
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
US20140296178A1 (en) * 2010-12-01 2014-10-02 Niiki Pharma Acquisition Corp. 2 Combination Therapy with a Gallium Complex
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
BR112017000800A8 (pt) * 2014-07-17 2023-04-25 Biocurity Holdings Inc Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
AU2017368135A1 (en) * 2016-11-30 2019-06-13 Tyme, Inc. Tyrosine derivatives and compositions comprising them
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN115768967B (zh) * 2020-09-28 2025-07-11 三菱重工业株式会社 蒸汽涡轮
WO2023101359A1 (ko) * 2021-11-30 2023-06-08 광주과학기술원 Pip4k2c 억제제를 유효성분으로 포함하는 암 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599903A (en) * 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5545621A (en) * 1991-04-29 1996-08-13 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5556942A (en) * 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5955432A (en) * 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5767147A (en) * 1995-04-21 1998-06-16 The Regents Of The University Of California Inhibition of glutathione transferase by haloenol lactones
DK0831877T3 (da) * 1995-06-07 2005-02-14 Telik Inc Metabolske virkninger af visse glutathionanaloge
US5880097A (en) * 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
US20030073837A1 (en) * 1998-12-31 2003-04-17 Langecker Peter J. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
JP2003522790A (ja) * 2000-02-17 2003-07-29 メルク エンド カムパニー インコーポレーテッド Ｃｏｘ−２選択的阻害薬を用いた前立腺癌の治療または予防
AU2002246827B2 (en) * 2000-12-22 2008-02-21 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound

Also Published As

Publication number Publication date
US20040138140A1 (en) 2004-07-15
CN101590229A (zh) 2009-12-02
WO2004045593A2 (en) 2004-06-03
TW200412933A (en) 2004-08-01
CN1711076A (zh) 2005-12-21
TWI323662B (en) 2010-04-21
CN101590229B (zh) 2012-12-05
CA2505377A1 (en) 2004-06-03
JP2006508980A (ja) 2006-03-16
BR0316364A (pt) 2005-10-04
US20080159980A1 (en) 2008-07-03
AR042051A1 (es) 2005-06-08
KR20050075018A (ko) 2005-07-19
AU2010200483A1 (en) 2010-03-04
EP1562564A2 (en) 2005-08-17
CN100508961C (zh) 2009-07-08
JP2010265305A (ja) 2010-11-25
WO2004045593A3 (en) 2004-08-12
MXPA05005200A (es) 2005-08-18

Similar Documents

Publication Publication Date Title
US20080159980A1 (en) Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy
US8207121B2 (en) Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
EA031099B1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
KR19990022395A (ko) 가역성 시스테인 프로테아제 억제제
KR20100137416A (ko) 암 치료법
JP4991107B2 (ja) コンブレタスタチンおよび抗癌剤からなる組成物
JP2006508980A5 (https=)
US20220088042A1 (en) Combination therapy including sapc-dops for the treatment of pancreatic cancer
JP2008543847A (ja) リポペプチドを用いてアポトーシスから保護するための方法
EA006295B1 (ru) Применение производных дистамицина для противоопухолевой терапии
HRP20020485A2 (en) Methods and compositions for levovirin
Schilder et al. New therapies for ovarian cancer
JP2011500650A (ja) 改良された抗腫瘍治療
WO2012076688A1 (en) Combination comprising a derivative of the family of the combretastatins and cetuximab
KR20200127891A (ko) 트리스 구조를 가지는 링커를 포함하는 리간드-약물 접합체
US10413564B2 (en) Compositions and methods for combating drug-resistant cancers
HK1128234A1 (en) Combination comprising combretastatin and anticancer agents

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted